Last reviewed · How we verify
Experimental: Rosuvastatin/Ezetimibe 10
This combination reduces LDL cholesterol by inhibiting HMG-CoA reductase (rosuvastatin) and blocking intestinal cholesterol absorption (ezetimibe).
This combination reduces LDL cholesterol by inhibiting HMG-CoA reductase (rosuvastatin) and blocking intestinal cholesterol absorption (ezetimibe). Used for Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction.
At a glance
| Generic name | Experimental: Rosuvastatin/Ezetimibe 10 |
|---|---|
| Also known as | Rosuzet tab 10/10 mg |
| Sponsor | Keun-Sik Hong |
| Drug class | Statin/ezetimibe combination |
| Target | HMG-CoA reductase; NPC1L1 transporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rosuvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, thereby lowering LDL cholesterol production. Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. Together, these complementary mechanisms produce additive LDL-lowering effects.
Approved indications
- Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction
Common side effects
- Myalgia
- Elevated liver enzymes
- Headache
- Gastrointestinal disturbance
Key clinical trials
- Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI (PHASE4)
- Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke (PHASE4)
- Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental: Rosuvastatin/Ezetimibe 10 CI brief — competitive landscape report
- Experimental: Rosuvastatin/Ezetimibe 10 updates RSS · CI watch RSS
- Keun-Sik Hong portfolio CI